Fixed Vocabulary
MCDA Regimes Applied to Psychedelic Markets
Current federal status: psilocybin, DMT, MDMA, ibogaine, and mescaline are Schedule I. DEA has proposed rescheduling psilocybin to Schedule III — not yet finalised. Zero legal access for non-research, non-ceremonial use.
Oregon Measure 110 (decriminalisation, repealed 2024), Colorado Prop 122 personal use provisions, Washington DC Initiative 81. Decriminalisation without legal supply does not address production or distribution harms and is politically reversible.
No current psychedelic jurisdiction. Alberta cannabis (15% licence cap) is the closest cannabis approximation. Would require state-licensed supply chain with advertising bans, plain packaging, and market concentration limits. The legislative window to establish this is before FDA pharmaceutical-track approval.
Where the sector is heading if pharmaceutical-track approval precedes non-commercial frameworks. Compass COMP360 approval + Polymorph A patent + therapy room IP = patent-holder controlled supply at market-rate pricing. Access determined by insurance coverage and ability to pay.
Five-Point Corporate Capture Mitigation Toolkit
Source: How to Regulate Cannabis, 3rd ed., 2022. Apply to every new psychedelic regulatory development and corporate transaction.
If No Criteria Are Met: 3-Year Implications
Cannabis Corporate Capture Comparators
These are the documented cases every psychedelic corporate development is measured against.
Largest single investment in cannabis history at time of deal. Constellation holds 4 of 7 board seats. Canopy subsequently acquired Acreage Holdings (US conditional deal), BioSteel, and This Works. Documents alcohol sector entry pattern Transform's toolkit is designed to prevent.
Tobacco industry entry. Exact pattern FCTC Article 5.3 is designed to prevent in regulated markets. Altria simultaneously held ~35% of JUUL Labs. Cronos subsequently entered US hemp market. Primary example of why Transform toolkit criterion 3 (alcohol/tobacco exclusion) is non-negotiable.
Second major tobacco actor entering cannabis. BAT also invested in Oxford Cannabinoid Technologies (OCT) for pharmaceutical-track CBD research. Pattern: tobacco sector hedging across recreational and pharmaceutical tracks simultaneously.
AB InBev entered cannabis via joint venture with Tilray for cannabis-infused beverages. Documents alcohol sector cross-market strategy — beverage alcohol companies entering cannabis while monitoring psychedelic markets.
Second alcohol-cannabis beverage JV. Truss Beverage Co. produces cannabis-infused beverages for Canadian market. Molson Coors subsequently wound down the venture in 2023 — documents difficulty of alcohol sector cannabis integration but not resolution of capture risk.
Cannabis REIT model: IIPR owns facilities and leases back to operators. Creates financial capture without equity stake — operators become dependent on REIT landlord. Novel capture vector not addressed in most state regulatory frameworks. Relevant to psychedelic facilitation centre real estate.
Psychedelic Corporate Actors Under Monitoring
Total disclosed investment: >$500m (2019-2023); MAPS raised >$120m for Phase 3 MDMA trials separately. Corporate actor data sourced to Marks & Cohen, HLR (2022) and Bashir, Georgetown GJIL (2024).
Focus: COMP360 (synthetic psilocybin) for treatment-resistant depression
Backers: Peter Thiel (early investor); ATHOS (Founders Fund affiliated)
IP strategy: Patent holder on crystalline psilocybin Polymorph A (US Patent '175, granted 2019). Broad WIPO process claims. Has indicated no intent to sign patent pledge (Marks & Cohen, HLR 2022). Also holds patents on therapy room design elements.
Regulatory track: FDA Breakthrough Therapy Designation for COMP360 in TRD. Pursuing pharmaceutical FDA approval track — approximates MCDA Regime 4 (free commercial market).
Focus: Portfolio model: psilocybin (COMP360 via Compass stake), ibogaine (DemeRx), R-ketamine (Perception Neuroscience), 5-MeO-DMT (Viridia Life Sciences), DMT (EntheogeniX), PCN-101
Backers: Peter Thiel (lead investor); Christian Angermayer
IP strategy: Holds portfolio of IP across subsidiary companies. Portfolio model replicates pharmaceutical venture capital structure across multiple compounds simultaneously.
Regulatory track: Multiple FDA IND applications across portfolio. Explicitly pharmaceutical-track across all compounds.
Focus: MM-120 (LSD tartrate) for generalised anxiety disorder; MM-402 (R-MDMA) for autism spectrum disorder; ibogaine program
Backers: JR Rahn (co-founder); various institutional investors post-NASDAQ listing
IP strategy: Patents on specific molecular formulations and dosing methods. MM-120 FDA Breakthrough Therapy Designation 2024.
Regulatory track: FDA pharmaceutical track across all programs.
Focus: CYB003 (deuterated psilocybin analog) for major depressive disorder; CYB004 (deuterated DMT) for generalised anxiety disorder
Backers: Various institutional investors
IP strategy: Deuterium modification strategy: altering molecular structure to create patentable analogs of compounds with prior art. Legal strategy specifically designed to circumvent natural compound patent challenges.
Regulatory track: FDA pharmaceutical track.
Focus: GH001 (inhaled 5-MeO-DMT) for treatment-resistant depression
Backers: Various institutional investors
IP strategy: Proprietary inhaled formulation and delivery method patents.
Regulatory track: FDA Breakthrough Therapy Designation. Pharmaceutical track.
Focus: BPL-003 (intranasal 5-MeO-DMT); psilocybin programs
Backers: Amanda Feilding / Beckley Foundation origins; private investors
IP strategy: Intranasal delivery formulation patents.
Regulatory track: FDA/EMA pharmaceutical track.
Focus: MDMA-assisted therapy; psilocybin research
Backers: Various impact investors
IP strategy: Stated open-science commitment. Reciprocity Trust model for Indigenous benefit sharing.
Regulatory track: FDA pharmaceutical track but with stated access commitments.
Focus: MDMA-assisted therapy for PTSD
Backers: MAPS non-profit; Lykos is commercial spin-off
IP strategy: MAPS holds IP; licensed to Lykos for commercialisation. FDA rejected Lykos NDA in August 2024 — requested additional Phase 3 trial.
Regulatory track: FDA NDA rejected August 2024. Resubmission timeline unclear.
Refresh Triggers
- Any new alcohol, tobacco, or pharma acquisition of a psychedelic sector actor
- Any jurisdiction adopting or abolishing licence caps for psychedelic operators
- Any FCTC Article 5.3 reference in psychedelic regulatory documentation
- Any MCDA or state-control language in official regulatory design documents
- Any new REIT or financial-sector entry into psychedelic real estate or supply chain
- Any Peter Thiel / Christian Angermayer portfolio company filing new psychedelic IP
- Any DEA rescheduling finalisation — opens window for state Tier 3 legislation
The aggregate picture across the eight psychedelic sector actors is unambiguous: every publicly traded psychedelic company is pursuing a pharmaceutical-track model that most closely approximates MCDA Regime 4 (free commercial market). Zero of Transform’s five capture-prevention criteria are met by any US psychedelic regulatory framework. The tobacco sector (Altria/Cronos, BAT/OrganiGram) and alcohol sector (Constellation/Canopy, AB InBev/Tilray) have already demonstrated in cannabis exactly what unmitigated corporate entry produces. The psychedelic sector is following the same trajectory, earlier.
The implications compound across tabs. Patent enclosure (Tab 2) forecloses the generic access that would make Tier 2 and Tier 3 viable. Without Tier 2 and Tier 3 (Tab 6), all legal access flows through licensed commercial operators — the exact corporate-capture endpoint Transform’s toolkit is designed to prevent. The window to embed capture-prevention criteria is the period before FDA approval establishes market incumbents. That window is open now and will close when the first pharmaceutical-track approval creates patent-holder market control.
The critical intervention point is at the state regulatory design stage — before licences are issued, before incumbents establish market position, before lobbying calcifies. Every state legislature considering psychedelic regulation in 2025-2027 is making a decision that will determine whether Failure Mode 2 is locked in or can be averted. Transform’s five-point toolkit provides the specific criteria. None of the current frameworks have applied them.
Subscribe to Corporate Capture Watch alerts
Receive the Monday 8am HST weekly intelligence digest when new developments are scored for this tab.
We store only the name and email you enter here, and use them only to send this digest. Every email carries an unsubscribe link, which removes the address immediately.